Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Tipo de estudo
Intervalo de ano de publicação
1.
Artigo em Inglês | MEDLINE | ID: mdl-29661882

RESUMO

Borrelia miyamotoi is an emerging relapsing fever (RF) Borrelia species that is reported to cause human disease in regions in which Lyme borreliosis is endemic. We recently showed that B. miyamotoi tick isolates are resistant to amoxicillin in vitro; however, clinical isolates have not been studied. Therefore, our aim was to show the antimicrobial susceptibility of recently obtained clinical isolates of B. miyamotoi A dilution series of various antibiotics was made in modified Kelly-Pettenkofer medium with 10% fetal calf serum. The susceptibilities of different B. miyamotoi clinical, B. miyamotoi tick, RF Borrelia, and Borrelia burgdorferisensu lato isolates were tested by measuring MICs through colorimetric changes and by counting motile spirochetes by dark-field microscopy after 72 h of incubation. The ceftriaxone and azithromycin MIC ranges of the six B. miyamotoi clinical isolates tested were 0.03 to 0.06 mg/liter and 0.0016 to 0.0032 mg/liter, respectively. These values are similar to MICs for RF Borrelia strains and B. miyamotoi tick isolates. All tested RF Borrelia strains were susceptible to doxycycline (microscopic MIC range, 0.0625 to 0.25 mg/liter). In contrast to the MICs of the tested B. burgdorferi sensu lato strains and in line with our previous findings, the amoxicillin MICs (range, 8 to 32 mg/liter) of all RF Borrelia strains, including B. miyamotoi clinical isolates, were above the clinical breakpoint for resistance (≤4 mg/liter). Clinical isolates of B. miyamotoi are highly susceptible to doxycycline, azithromycin, and ceftriaxone in vitro Interestingly, as described previously for tick isolates, amoxicillin shows poor in vitro activity against B. miyamotoi clinical isolates.


Assuntos
Amoxicilina/farmacologia , Antibacterianos/farmacologia , Azitromicina/farmacologia , Borrelia/efeitos dos fármacos , Borrelia/isolamento & purificação , Ceftriaxona/farmacologia , Doxiciclina/farmacologia , Animais , Humanos , Ixodes/microbiologia , Testes de Sensibilidade Microbiana , Febre Recorrente/tratamento farmacológico , Febre Recorrente/microbiologia
2.
Genome Announc ; 6(1)2018 Jan 04.
Artigo em Inglês | MEDLINE | ID: mdl-29301891

RESUMO

Here, we report the whole-genome sequence of six clinical Borrelia miyamotoi isolates from the Russian Federation. Using two independent next-generation sequencing platforms, we determined the complete sequence of the chromosome and several plasmids. All strains have an Asian genotype with 99.8% chromosome nucleotide similarity with B. miyamotoi strain FR64b.

3.
Emerg Infect Dis ; 17(10): 1816-23, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22000350

RESUMO

Borrelia miyamotoi is distantly related to B. burgdorferi and transmitted by the same hard-body tick species. We report 46 cases of B. miyamotoi infection in humans and compare the frequency and clinical manifestations of this infection with those caused by B. garinii and B. burgdorferi infection. All 46 patients lived in Russia and had influenza-like illness with fever as high as 39.5°C; relapsing febrile illness occurred in 5 (11%) and erythema migrans in 4 (9%). In Russia, the rate of B. miyamotoi infection in Ixodes persulcatus ticks was 1%-16%, similar to rates in I. ricinus ticks in western Europe and I. scapularis ticks in the United States. B. miyamotoi infection may cause relapsing fever and Lyme disease-like symptoms throughout the Holarctic region of the world because of the widespread prevalence of this pathogen in its ixodid tick vectors.


Assuntos
Borrelia/isolamento & purificação , Febre Recorrente/diagnóstico , Antibacterianos/uso terapêutico , Anticorpos Antibacterianos/sangue , Anticorpos Antibacterianos/imunologia , Borrelia/genética , Borrelia/imunologia , Doxiciclina/uso terapêutico , Humanos , Imunoglobulina M/sangue , Imunoglobulina M/imunologia , Filogenia , RNA Ribossômico 16S/genética , Recidiva , Febre Recorrente/tratamento farmacológico , Febre Recorrente/microbiologia , Federação Russa
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...